Pipeline
Oncology
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-β1/COX-2
Gene Targets:
TGF-β1/COX-2
Indications:

isSCC

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

isSCC

US

isSCC

China (MRCT)52

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

BCC

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

BCC

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer1 (Basket) **

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer1 (Basket) **

US

Liver Cancer1 (Basket) **

China (MRCT)3

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer, combo with anti-PD-(L)1

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer, combo with anti-PD-(L)1

US

Commercial Rights:
Global
View More+
STP707
More+
TGF-β1/COX-2
Gene Targets:
TGF-β1/COX-2
Indications:

Liver Cancer1 (Basket)**

Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Liver Cancer1 (Basket)**

US

Liver Cancer1 (Basket)**

China (MRCT)4

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:
cSCC
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
cSCC
US
Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:
NSCLC
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
NSCLC
US
Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2
Indications:
Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1
US
Commercial Rights:
Global
View More+
STP355
More+
TGF-β1/VEGFR2
Gene Targets:
TGF-β1/VEGFR2
Indications:
Pan Cancer
Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Pan Cancer
US
Commercial Rights:
Global
View More+
STP369
More+
BCL-xL/MCL-1
Gene Targets:
BCL-xL/MCL-1
Indications:
Head & Neck cancer/BC
Delivery Platform:
PNP-IT / IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Head & Neck cancer/BC
US
Commercial Rights:
Global
View More+
STP779
More+
TGF-β1/SULF-2
Gene Targets:
TGF-β1/SULF-2
Indications:
Liver Cancer/ Lung Cancer/ Pancreatic Cancer
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Liver Cancer/ Lung Cancer/ Pancreatic Cancer
US
Commercial Rights:
Global
View More+
STP302
More+
mir-150
Gene Targets:
mir-150
Indications:
Colorectal Carcinoma
Delivery Platform:
PNP-IT / IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Colorectal Carcinoma
Commercial Rights:
OL China
View More+
STP902
More+
RAF-1
Gene Targets:
RAF-1
Indications:
Breast cancer
Delivery Platform:
PNP-IT / IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Breast cancer
Commercial Rights:
Global
View More+
Fibrosis
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-β1/COX-2 
Gene Targets:
TGF-β1/COX-2 
Indications:
Keloid scarless healing**
Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Keloid scarless healing**

US

Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2 
Indications:
Hypertrophic scarring
Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Hypertrophic scarring
US
Hypertrophic scarring

China(MRCT)5

Hypertrophic scarring

China

Commercial Rights:
Global
View More+
STP707
More+
TGF-β1/COX-2 
Gene Targets:
TGF-β1/COX-2 
Indications:
Liver Fibrosis (PSC)
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Liver Fibrosis (PSC)
US
Liver Fibrosis (PSC)
China(MRCT)
Commercial Rights:
Global
Gene Targets:
TGF-β1/COX-2 
Indications:
Lung Fibrosis
Delivery Platform:
PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Lung Fibrosis
US
Commercial Rights:
Global
View More+
Medical Aesthetic
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP705*
More+
TGF-ß1/COX-2
Gene Targets:
TGF-ß1/COX-2
Indications:

Fat scuipting

Delivery Platform:
PNP-IT
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Fat scuipting

US

Commercial Rights:
Global
View More+
Antiviral
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP702
More+
M1/PA
Gene Targets:
M1/PA
Indications:

Influenza

Delivery Platform:
Airway / PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Influenza

US
Commercial Rights:
OL China
View More+
STP908
More+
ORF1Ab/N-protein
Gene Targets:
ORF1Ab/N-protein
Indications:

Covid-19

Delivery Platform:
Airway / PNP-IV
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Covid-19

US

Commercial Rights:
Global
View More+
RIM730
More+
SARS-CoV2
Gene Targets:
SARS-CoV2
Indications:

Covid-19 vaccine

Delivery Platform:
LNP​ Intramuscular
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Covid-19 vaccine

US

Commercial Rights:
Global
View More+
STP909
More+
VP16/18-E7
Gene Targets:
VP16/18-E7
Indications:
HPV/Cervical Cancer
Delivery Platform:
PNP-IV/Topical
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
HPV/Cervical Cancer
Commercial Rights:
Global
View More+
GaINAc-RNAi triggers
iconArrow
Candidate
Gene Targets
Indications
Delivery Platform
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Commercial Rights
STP122G
More+
Factor XI
Gene Targets:
Factor XI
Indications:

Anticoagulant

Delivery Platform:
GalAhead™​ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III

Anticoagulant

US

Commercial Rights:
Global
View More+
STP133G
More+
PCSK9/ApoC3
Gene Targets:
PCSK9/ApoC3
Indications:
Cardiometabolic
Delivery Platform:
GalAhead™ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Cardiometabolic
Commercial Rights:
Global
View More+
STP144G
More+
Complement Factor B
Gene Targets:
Complement Factor B
Indications:
Complement-mediated diseases
Delivery Platform:
GalAhead™​ subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Complement-mediated diseases
Commercial Rights:
Global
View More+
STP135G
More+
PCSK9
Gene Targets:
PCSK9
Indications:
Hypercholesterolemia (PCSK9)
Delivery Platform:
PDoV-GalNAc subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
Hypercholesterolemia (PCSK9)
Commercial Rights:
Global
View More+
STP155G
More+
HBV sequences
Gene Targets:
HBV sequences
Indications:
HBV
Delivery Platform:
PDoV-GalNAc subcutaneous
Pre-clinical
IND Enabling
IND
PHASE I
PHASE II
PHASE III
HBV
Commercial Rights:
Global
View More+

Notes:

*   denotes our core product

 

** denotes orphan drug

Abbreviations:

isSCC = cutaneous squamous cell carcinoma in situ;

BCC = basal cell carcinoma;

cSCC = metastatic cutaneous squamous cell carcinoma;

NSCLC = non-small cell lung cancer;

CRC = colorectal carcinoma;

BC = bladder cancer; PSC= primary sclerosing cholangitis;

PNP = our polypeptide nanoparticle (PNP) RNAi delivery platform;

PNP-IT = PNP platform formulated for intratumoral administration;

PNP-IV = PNP platform formulated for intravenous administration;

GalAhead = our GalNAc RNAi delivery platform that conjugates GalNAc moieties to RNAi triggers;

PDoV-GalNAc = our GalNAc RNAi delivery platform that conjugates GalNAc moieties to Peptide Docking Vehicle (PDoV) peptide linkers and up to two siRNAs to the peptide;

LNP = lipid nanoparticle (LNP) formulation for delivery of mRNA;

HPV = human papilloma virus; HBV=hepatitis B virus; OL China= out-licensed mainland China, Hong Kong, Macau and Taiwan rights under agreement with Walvax but we retain the rights for rest of the world; 

MRCT = multi regional clinical trial in which we will be the sponsor for all clinical trial sites.

 

1. Liver cancer (basket) includes cholangiocarcinoma, hepatocellular carcinoma, liver metastases etc.

2. We filed our IND in China, which is currently awaiting approval from NMPA, for study sites in China. The study sites will be part of a global multicenter study for our Phase IIb clinical trial for isSCC.

3. We expect to file the IND in China as part of the global multicenter clinical trials.

4. We expect to file the IND solely for HCC in China as part of the global multicenter clinical trials.

5. Studies in combination with anti-PD-(L)1 inhibitors conducted pursuant to collaborations with Innovent and Shanghai Junshi.

6. Research and development conducted by our subsidiary RNAimmune.